Boston Scientific misses 2026 guidance as Boston Scientific stock faces a reset
Published on 10/01/2026 at 11:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On September 8, 2026, Reuters reported that Boston Scientific no longer expected to meet its third-quarter and full-year 2026 sales and adjusted earnings guidance after a cybersecurity incident disrupted manufacturing, order processing and shipments. The event gives Boston Scientific stock a reset point because the company must now prove that operational recovery can protect its underlying growth profile.
Cyberattack changes 2026 outlook
The company had previously projected adjusted earnings of USD 3.28-3.32 per share for fiscal 2026 and adjusted earnings of USD 0.80-0.82 per share for the third quarter. Reuters reported that Boston Scientific planned to provide an updated operational and financial outlook with its third-quarter results on October 28, 2026.
Boston Scientific said major distribution centers were processing and shipping orders at or above normal levels, while sterilization facilities were operational and manufacturing had resumed across most global facilities. That recovery matters because the disruption affected both supply execution and the timing of customer orders.
Second-quarter growth provides a benchmark
Boston Scientific reported USD 5.442 billion in net sales for the second quarter of 2026, with reported growth of 7.50 percent and operational growth of 7.00 percent. The finance data show diluted earnings per share of USD 0.61 for the same quarter, while operating margin was 22.00 percent.
The second-quarter numbers establish the operating base that the October update must defend. They also show why the cyber event is more than a short-term share-price issue: a lower sales trajectory would affect earnings leverage even if manufacturing and distribution continue to normalize.
Analyst target falls as risks widen
According to Yahoo Finance on September 21, 2026, Oppenheimer analyst Suraj Kalia cut the price target from USD 85.00 to USD 65.00 while maintaining an Outperform rating. The report cited the eight-day cybersecurity disruption and competitive pressure in left atrial appendage closure and electrophysiology.
The same report said WATCHMAN global sales grew 4.20 percent organically in fiscal second-quarter 2026, while global electrophysiology growth reached 9.10 percent organically. Those figures separate the temporary cyber disruption from the broader product-specific questions facing Boston Scientific.
NYSE value and recovery test
Boston Scientific was last at USD 43.65 on the NYSE on September 30, 2026 at 4:00 p.m. ET. Its 52-week range was USD 42.20 to USD 105.65, placing the latest quote USD 1.45 above the low and USD 62.00 below the high. Market capitalization stood at USD 64.9 billion as of September 30, 2026.
Boston Scientific stock facts
- Company: Boston Scientific Corporation
- Ticker: BSX
- Primary exchange: NYSE
- Market capitalization: USD 64.9 billion (as of September 30, 2026)
- 52-week range: USD 42.20-105.65 (as of September 30, 2026)
- Sector / Industry: Healthcare / Medical Devices
